UBS Group’s Oruka Therapeutics ORKA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.4M | Sell |
212,271
-58,742
| -22% | -$2.04M | ﹤0.01% | 3290 |
|
|
2025
Q4 | $8.21M | Buy |
271,013
+184,453
| +213% | +$5.14M | ﹤0.01% | 3501 |
|
|
2025
Q3 | $1.66M | Sell |
86,560
-24,086
| -22% | -$357K | ﹤0.01% | 5135 |
|
|
2025
Q2 | $1.24M | Buy |
110,646
+76,763
| +227% | +$800K | ﹤0.01% | 5253 |
|
|
2025
Q1 | $348K | Buy |
33,883
+8,721
| +35% | +$109K | ﹤0.01% | 6128 |
|
|
2024
Q4 | $488K | Buy |
+25,162
| New | +$614K | ﹤0.01% | 5861 |
|
|
2024
Q1 | – | Sell |
-94
| Closed | -$1.92K | – | 10141 |
|
|
2023
Q4 | $1.92K | Buy |
94
+84
| +840% | +$1.89K | ﹤0.01% | 8196 |
|
|
2023
Q3 | $251 | Buy |
+10
| New | +$245 | ﹤0.01% | 8653 |
|
|
2023
Q2 | – | Sell |
-149
| Closed | -$3.56K | – | 9794 |
|
|
2023
Q1 | $3.56K | Buy |
149
+24
| +19% | +$632 | ﹤0.01% | 8302 |
|
|
2022
Q4 | $3.56K | Sell |
125
-93
| -43% | -$2.38K | ﹤0.01% | 9494 |
|
|
2022
Q3 | $5K | Sell |
218
-159
| -42% | -$4.49K | ﹤0.01% | 9244 |
|
|
2022
Q2 | $11K | Sell |
377
-42
| -10% | -$1.19K | ﹤0.01% | 7860 |
|
|
2022
Q1 | $12K | Sell |
419
-213
| -34% | -$5.28K | ﹤0.01% | 8205 |
|
|
2021
Q4 | $16K | Buy |
+632
| New | +$19K | ﹤0.01% | 8182 |
|
|
2021
Q3 | – | Sell |
-447
| Closed | -$19K | – | 10185 |
|
|
2021
Q2 | $19K | Buy |
+447
| New | +$18.6K | ﹤0.01% | 7409 |
|
|
2021
Q1 | – | Sell |
-128
| Closed | -$6K | – | 9565 |
|
|
2020
Q4 | $6K | Buy |
128
+51
| +66% | +$2.54K | ﹤0.01% | 7781 |
|
|
2020
Q3 | $4K | Buy |
+77
| New | +$5.43K | ﹤0.01% | 7449 |
|
|
2020
Q2 | – | Sell |
-3
| Closed | – | – | 8432 |
|
|
2020
Q1 | $0 | Sell |
3
-252
| -99% | -$13.7K | ﹤0.01% | 8500 |
|
|
2019
Q4 | $17K | Buy |
+255
| New | +$16.3K | ﹤0.01% | 7006 |
|
|
2019
Q3 | – | Sell |
-151
| Closed | -$13K | – | 8315 |
|
|
2019
Q2 | $13K | Buy |
+151
| New | +$13.6K | ﹤0.01% | 6910 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 8254 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 8360 |
|
|
2018
Q3 | – | Sell |
-24
| Closed | -$3.1K | – | 8325 |
|
|
2018
Q2 | $3K | Buy |
+24
| New | +$2.82K | ﹤0.01% | 7658 |
|
|
2018
Q1 | – | Sell |
-26
| Closed | -$7K | – | 8227 |
|
|
2017
Q4 | $7K | Buy |
26
+7
| +37% | +$2.03K | ﹤0.01% | 7249 |
|
|
2017
Q3 | $5K | Buy |
+19
| New | +$6.76K | ﹤0.01% | 7242 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 8044 |
|
|
2017
Q1 | – | Sell |
-5
| Closed | -$2.79K | – | 8043 |
|
|
2016
Q4 | $3K | Buy |
+5
| New | +$2.66K | ﹤0.01% | 7440 |
|
|
2016
Q3 | – | Sell |
-7
| Closed | -$4.51K | – | 7980 |
|
|
2016
Q2 | $4K | Buy |
+7
| New | +$5.18K | ﹤0.01% | 7251 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 8284 |
|
|
2015
Q4 | – | Sell |
-5
| Closed | -$5.66K | – | 8622 |
|
|
2015
Q3 | $5K | Buy |
+5
| New | +$7.62K | ﹤0.01% | 7733 |
|
|
2015
Q2 | – | Sell |
-5
| Closed | -$6.57K | – | 8902 |
|
|
2015
Q1 | $6K | Sell |
5
-10
| -67% | -$11.7K | ﹤0.01% | 8023 |
|
|
2014
Q4 | $21K | Buy |
+15
| New | +$22.6K | ﹤0.01% | 7614 |
|
Other funds holding ORKA
VA
FFM
PBA
RI
DTC
VCM
APM
UBS Group's ORKA Position: Q1 2026 in Review
UBS Group reduced its Oruka Therapeutics (ORKA) stake by 22% in Q1 2026, selling an estimated $2.04M and leaving 212,271 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3290.
UBS Group first reported a position in ORKA in Q4 2014 and has held it in 28 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.
- UBS Group held 212,271 shares of Oruka Therapeutics worth $10.4M as of Q1 2026.
- UBS Group sold 58,742 Oruka Therapeutics shares in Q1 2026, an estimated $2.04M.
- Oruka Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3290 holding.
- UBS Group first reported a position in Oruka Therapeutics in Q4 2014 and has held it in 28 quarters since.
- 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.